Latest Strategic Appointments News

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Toubani Resources has made significant strides in advancing its Kobada Gold Project, reporting promising drilling results and securing a substantial A$395 million funding package to support project development.

Bayan Mining and Minerals Limited reports significant progress in its rare earth and gold exploration projects, highlighted by high-grade assay results and strategic land acquisitions in California and Nevada.

Golden Mile Resources is advancing exploration at its Aurora Gold Prospect in Arizona, launching detailed geological mapping and soil sampling to refine high-grade gold targets ahead of maiden drilling.

Lindian Resources has appointed DRA Pacific to lead the Kangankunde Stage 2 Expansion Study, aiming to scale rare earths production amid strong market demand. This move follows the recent Final Investment Decision for Stage 1, targeting first production in 2026.

VBX Limited reports promising low-silica bauxite discoveries at East Kalumburu A near its flagship Wuudagu project, alongside key strategic appointments and ongoing drilling programs advancing the project towards a targeted DFS completion in early 2026.

EVE Health Group has appointed Dr Fiona Cousins as the inaugural member of its Scientific Advisory Board, reinforcing its commitment to advancing treatments for dysmenorrhoea and endometriosis ahead of the commercial launch of Dyspro™.

Elixinol Wellness has raised $2.5 million through a well-supported placement and appointed industry veteran Gavin Evans as strategic advisor to drive its next phase of growth and operational reset.

Metallium Ltd has appointed former U.S. Deputy Assistant Secretary of Defense Travis Langster to its U.S. advisory board, aiming to strengthen ties with government and industry for critical metals supply chain resilience.

Omni Bridgeway Limited has reported a robust FY25 with full debt repayment, strong portfolio returns, and strategic capital raises positioning it as a leader in legal finance. The company’s disciplined cost management and validated fair value approach underpin its confident outlook for FY26.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

Antipa Minerals reports exceptional high-grade gold and copper intersections at its 100%-owned Minyari Project, reinforcing its resource growth and advancing its Pre-feasibility Study towards production.